Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development
Cancer Treatment Reviews · 2024-11 · 130 · 102824
DOI: 10.1016/j.ctrv.2024.102824 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2024-11. Verfasst von Carla Corvaja und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Oncology, European Institute of Oncology IRCCS, Via G. Ripamonti, 435 - 20141 Milan, Italy. Hauptthemen laut MEDLINE: ErbB Receptors, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 93-mal zitiert (Crossref) und nennt 102 Literaturangaben. Gefördert von: Ministry of Health.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Thoracic Oncology, European Institute of Oncology IRCCS, Via G. Ripamonti, 435 - 20141 Milan, Italy.
- Division of Thoracic Oncology, European Institute of Oncology IRCCS, Via G. Ripamonti, 435 - 20141 Milan, Italy. Electronic address: Antonio.Passaro@ieo.it.
Förderung
- Ministry of Health
Zitieren
APA
Corvaja, C., Passaro, A., Attili, I., Aliaga, P. T., Spitaleri, G., Signore, E. D., & de Marinis, F. (2024). Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development. Cancer Treatment Reviews, 130, 102824. https://doi.org/10.1016/j.ctrv.2024.102824
Vancouver
Corvaja C, Passaro A, Attili I, Aliaga PT, Spitaleri G, Signore ED, et al. Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development. Cancer Treatment Reviews. 2024;130:102824. doi:10.1016/j.ctrv.2024.102824
BibTeX
@article{Corvaja2024,
author = {Corvaja, Carla and Passaro, Antonio and Attili, Ilaria and Aliaga, Pamela Trillo and Spitaleri, Gianluca and Signore, Ester Del and de Marinis, Filippo},
title = {Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development},
journal = {Cancer Treatment Reviews},
year = {2024},
volume = {130},
pages = {102824},
doi = {10.1016/j.ctrv.2024.102824}
}
EUVIMED